Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02969122
Other study ID # 2016YJZ35
Secondary ID
Status Recruiting
Phase N/A
First received November 12, 2016
Last updated November 23, 2016
Start date November 2016
Est. completion date December 2023

Study information

Verified date November 2016
Source Peking University
Contact Rulin Miao, M.D.
Phone 86-10-88196598
Email miaorulin@outlook.com
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Gastric cancer with positive is defined as stage IV disease in 7th AJCC/UICC TNM staging system. Controversy exists on the treatment of this part of patients. This trial aimed to explore the optimal treatment strategy for stage IV gastric cancer with positive peritoneal cytology as the only non-curable factor.


Description:

In the 7th AJCC/UICC TNM staging system, gastric cancer with positive peritoneal cytology (CY+) is defined as stage IV disease. In NCCN clinical practice guidelines, it is suggested that positive peritoneal cytology in the absence of visible peritoneal implants should be considered as M1 disease and surgery as initial treatment is not recommended for patients with positive peritoneal cytology. However, in the Japanese gastric cancer treatment guidelines 2014, it is suggested that standard gastrectomy can be proposed for patients with no other non-curative factors and if the CY+ status was revealed after surgery, postoperative treatment with S-1 can be recommended as the tentative standard. Previous studies have also proved that extensive intraperitoneal lavage(EIPL) and Hyperthermic Intraperitoneal Chemotherapy(HIPEC) are effective methods for the treatment of peritoneal metastasis.

In order to optimize the treatment strategy of this part of patients, this trial is designed to compare the effectiveness of 2 treatment strategies.


Recruitment information / eligibility

Status Recruiting
Enrollment 59
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Pathologically diagnosed gastric adenocarcinoma with endoscopic biopsy;

- Pretreatment clinical stage with computed tomography and/or endoscopic ultrasonography;

- Clinical stage cT2-4 N0-3 M0;

- Standard gastrectomy with D2 lymphadenectomy is needed according to the clinicians' evaluation;

- ECOG performance score =2, with tolerance of standard gastrectomy and D2 lymphadenectomy;

- Positive peritoneal cytology;

- Signed informed consent.

Exclusion Criteria:

- Remnant gastric cancer, recurrence gastric cancer or multi-primary cancers;

- Intraoperative identified other unresectable factors including other metastasis except positive peritoneal cytology;

- Postoperative pathologically diagnosed as non adenocarcinoma;

- Pregnant or lactate women;

- Child-bearing period adults who refuse to birth control during the trial;

- Uncontrolled epilepsy, CNS disease or mental disorder that may influence the compliance of the patient;

- Severe/active heart disease, including but not limited to acute coronary syndrome, congestive heart failure with less than NYHA II cardiac function, severe arrhythmia that needs drug control, cardiac infarction within 12 month;

- Organ transplantation patients who needs immune suppression therapy;

- Patients who needs emergency surgery because of bleeding, perforation or obstruction.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
standard gastrectomy with D2 lymphadenectomy
standard distal or total gastrectomy and accorded D2 lymphadenectomy
hyperthermic intraperitoneal chemotherapy
Intraperitoneal docetaxel of 100mg/m2 at 42? for 30 minutes
Extensive intraperitoneal lavage
Lavage of peritoneal cavity with 1000ml saline for 10 times
Other:
Preoperative chemotherapy
Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
Postoperative chemotherapy
SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.

Locations

Country Name City State
China Gastrointestinal Cancer Center, Peking University Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival 3 year No
Secondary peritoneal recurrence rate 3 year No
Secondary Recurrence free survival 3 year No
Secondary rate of peritoneal cytology converted to negative 7 days After the second time laparoscopic staging and peritoneal cytology examination No
Secondary morbidity and mortality of HIPEC and EIPL 30 days after HIPEC and EIPL procedures Yes
See also
  Status Clinical Trial Phase
Completed NCT03313700 - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer N/A
Recruiting NCT05645198 - The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy Phase 4
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00935779 - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer N/A
Completed NCT00144378 - Irinotecan Versus Only Best Supportive Care for Gastric Cancer Phase 3
Completed NCT00290966 - Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT03348150 - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Phase 3
Not yet recruiting NCT06085677 - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Completed NCT01482299 - RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression Phase 2
Active, not recruiting NCT03760822 - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients Phase 2
Recruiting NCT00509964 - Second-Line Irinotecan vs. ILF for AGC Phase 2
Completed NCT04889859 - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy N/A
Completed NCT03071237 - The Origin of Infrapyloric Artery
Recruiting NCT05184803 - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer Phase 2
Completed NCT05714878 - Multimodal Prehabilitation for Resectable Gastric Cancer N/A
Completed NCT00142038 - Docetaxel and Capecitabine in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04056260 - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT04744649 - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Phase 2
Recruiting NCT05640609 - Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer Phase 1/Phase 2